Esophageal squamous cell carcinoma

Related records

Broader conditions (21)

• Cancer
• Cancer or benign tumor
• Carcinoma
• Carcinoma of esophagus
• Digestive system cancer
• Digestive system carcinoma
• Digestive system disorder
• Digestive system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Esophageal cancer
• Esophageal disorder
• Human disease
• Neoplasm
• Neoplasm of esophagus
• Neoplastic disease or syndrome
• Squamous cell carcinoma
• Squamous cell neoplasm

Narrower conditions (4)

• Esophageal adenosquamous carcinoma
• Esophageal basaloid carcinoma
• Esophagus verrucous carcinoma
• Undifferentiated carcinoma of esophagus

Trials (666)

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
• A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
• A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
• A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
• A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
• A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
• A Clinical Trial of Esophagectomy for Esophageal Carcinoma
• A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
• A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
• A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
• A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
• A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
• A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
• A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
• A Multicenter Cancer Biospecimen Collection Study
• A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
• A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
• A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
• A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Approved drugs (1)

• Tislelizumab

Drugs in development (78)

• Acetaminophen Phase 1
• Adebrelimab Phase 2
• Afatinib Phase 2
• Albumin human Phase 2
• Alpelisib Phase 1
• Atezolizumab Phase 3
• Avelumab Phase 2
• Benmelstobart Phase 2
• Bevacizumab Phase 2
• Cadonilimab Phase 2
• Camrelizumab Phase 3
• Capecitabine Phase 3
• Carboplatin Phase 3
• Catequentinib Phase 2
• Celecoxib Phase 2
• Cetuximab Phase 3
• Cisplatin Phase 3
• Dalpiciclib Phase 2
• Decitabine Phase 2
• Dexamethasone Phase 1

Other linked drugs (1)

• Trilaciclib